SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support

Sponsor
BrightOutcome (Industry)
Overall Status
Completed
CT.gov ID
NCT05562583
Collaborator
Northwestern University (Other)
15
1
1
31
0.5

Study Details

Study Description

Brief Summary

The goal of the proposed study, is to adapt a positive emotion intervention for Alzheimer's Disease (AD) caregivers into a self-guided online format that incorporates social connection components and adaptive system feedback mechanisms to promote intervention adherence. Previous tests of the facilitated version of the program, called SAGE-LEAF (Social Augmentation to self-Guided Electronic delivery of the Life Enhancing Activities for Family caregivers), have shown efficacy for improving well-being in dementia caregivers. If effective, the SAGE-LEAF program can be disseminated to Alzheimer's caregivers nationwide through AD treatment and research centers.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: SAGE LEAF
N/A

Detailed Description

The prevalence of Alzheimer's Disease (AD) and other dementias is steadily climbing and predicted to affect as many as 16 million Americans by 2050. In 2016, 59% of dementia caregivers reported experiencing high levels of emotional and physical stress, and the risk that the chronic stress of dementia caregiving places on caregivers for developing a range of physical and mental health issues is extensively documented. Caregiving-related stress contributes to social isolation, loneliness, and physical illness and increases the risk of caregiver death. Interventions for dementia caregivers have primarily focused on reducing negative emotions and burden. However, over the past few decades, it has become clear that positive emotions are uniquely related to better psychological and physical well-being, independent of the effects of negative emotion suggesting that an intervention that specifically targets positive emotion holds promise for improving caregiver well-being and, ultimately, quality of care for the individual living with AD. The investigators' recent randomized trial of the positive emotion skills intervention, delivered by trained facilitators via the web in N = 170 family caregivers of people with dementia resulted in significant improvements in caregiver psychological well being. However, facilitator-delivered interventions are costly and difficult to implement with fidelity on a large scale. Furthermore, a major challenge to advancing behavioral interventions delivered by trained facilitators is assuring fidelity. The investigators have developed a self-guided online version of the intervention that has shown feasibility and acceptability in several samples, but this version does not capture the critical social connection aspects of the facilitator-delivered intervention. The investigators propose to take the next step toward closing the science-to-practice gap for the positive emotion regulation intervention by tailoring the self-guided online version specifically for dementia caregivers that incorporates the social connection components to combat the loneliness and isolation experienced by many Alzheimer's caregivers. The intervention, called SAGE-LEAF (Social Augmentation of self-Guided Electronic delivery of the Life Enhancing Activities for Family caregivers) is in response to the National Institute on Aging's PAR-18-588 "Assistive Technology for Person's with Alzheimer's Disease and Related Dementias and Their Caregivers." The SAGE-LEAF intervention leverages the lessons learned from the original LEAF project and adapts its positive emotion intervention to AD caregivers in a self-guided format while incorporating social connection components and adaptive system feedback mechanisms to promote intervention adherence.

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
Actual Study Start Date :
Sep 30, 2019
Actual Primary Completion Date :
Apr 30, 2022
Actual Study Completion Date :
Apr 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention (single arm)

5 session self-guided online delivered positive emotion regulation intervention with social components.

Behavioral: SAGE LEAF
SAGE LEAF covers 8 skills and each skill has related home-practice activities that "unlock" every week. Each week will consist of 1-2 days of didactic material and 5-6 days of real-life home practice. Participants can access the skills at their own leisure and as often as they'd like within that week. Participants cannot skip modules with didactic material and can only progress to the next lesson if they have completed the current one. However, participants can return to old lessons or exercises if they choose to do so at a later time.

Outcome Measures

Primary Outcome Measures

  1. Percentage of skill pages in SAGE-LEAF accessed by a participant [Post-study (week 6)]

    This is to measure adherence to SAGE-LEAF intervention. Score range: 0-100%. A higher percentage means better adherence to the SAGE-LEAF intervention.

  2. Percentage of participants completed post-study assessment [Post-study (week 6)]

    This is to measure the retention rate of participants completing the study. Score range: 0-100%. A higher percentage means better participant retention.

  3. Willingness to recommend SAGE-LEAF to other AD caregivers [Post-study (week 6)]

    This is to measure the acceptability of SAGE-LEAF. Score range: 1-5. A higher score indicates higher acceptability.

  4. System Usability Scale [Post-study (week 6)]

    This is to measure the usability of SAGE-LEAF. Score range: 0-100. A higher score indicates better usability.

Secondary Outcome Measures

  1. Zarit Burden Interview [Pre-study and post-study (week 6)]

    Measuring caregiving burden. Score range: 0-88. Higher scores indicate greater burden.

  2. Oberst Caregiving Burden Scale [Pre-study and post-study (week 6)]

    Measuring caregiving burden in terms of time and difficulty. Score range: 15-75. Higher scores indicate higher levels of caregiver burden.

  3. Positive Aspects of Caregiving Scale [Pre-study and post-study (week 6)]

    Measuring positive aspects to caregiving for dementia patients. Score range: 5-45. Higher scores indicate better caregivers' outlook on life and self-affirmations.

  4. Role Captivity sub-scale of Caregiver Reaction Assessment [Pre-study and post-study (week 6)]

    Measuring role captivity in caregiving. Score 1-4. Higher scores indicate stronger feelings of role captivity.

  5. Overload sub-scale of Caregiver Reaction Assessment [Pre-study and post-study (week 6)]

    Measuring the feeling of overload in caregiving. Score 1-4. Higher scores indicate stronger feelings of overload.

  6. Caregiving Mastery subscale of the Caregiving Appraisal Measure [Pre-study and post-study (week 6)]

    Measuring caregiving mastery. Score range: 1-5. Higher scores indicate better caregiving mastery.

  7. Cohen's perceived stress scale [Pre-study and post-study (week 6)]

    Measuring perceived stress. Score range: 0-40. Higher scores indicate higher levels of perceived stress

  8. Positive Affect in Differential Emotions Scale [Pre-study and post-study (week 6)]

    Measuring positive emotions. Score range: 1-5. Higher scores indicate higher levels of positive emotions.

  9. Negative Affect in Differential Emotions Scale [Pre-study and post-study (week 6)]

    Measuring positive emotions. Score range: 1-5. Higher scores indicate higher levels of negative emotions.

  10. Patient-Reported Outcomes Measurement Information System - Depressioin [Pre-study and post-study (week 6)]

    Measuring depression level. Score range: 20-80. Higher scores indicate higher depression levels.

  11. Patient-Reported Outcomes Measurement Information System - Anxiety [Pre-study and post-study (week 6)]

    Measuring anxiety level. Score range: 20-80. Higher scores indicate higher anxiety levels.

  12. Patient-Reported Outcomes Measurement Information System - Sleep Disturbance [Pre-study and post-study (week 6)]

    Measuring sleep disturbance level. Score range: 20-80. Higher scores indicate higher levels of sleep disturbance.

  13. Patient-Reported Outcomes Measurement Information System - Meaning and Purpose [Pre-study and post-study (week 6)]

    Measuring one's sense of life having purpose and that there are good reasons for living. Score range: 20-80. Higher scores indicate hopefulness, optimism, goal-directedness, and feelings that one's life is worthy.

  14. Patient-Reported Outcomes Measurement Information System - Social Isolation [Pre-study and post-study (week 6)]

    Measuring perceptions of being avoided, excluded, detached, disconnected from, or unknown by, others. Score range: 20-80. Higher scores indicate higher levels of perception of social isolation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults age 18 and over who identify as the primary caregiver of a family member with Alzheimer's Disease

  • Co-reside with the family caregiver

  • Speak and read English

  • Have internet access and a reliable email address

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611

Sponsors and Collaborators

  • BrightOutcome
  • Northwestern University

Investigators

  • Principal Investigator: DerShung Yang, PhD, BrightOutcome, Inc.
  • Principal Investigator: Judith T Moskowitz, PhD, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
DerShung Yang, PhD, President, BrightOutcome
ClinicalTrials.gov Identifier:
NCT05562583
Other Study ID Numbers:
  • R43AG065080
First Posted:
Oct 3, 2022
Last Update Posted:
Oct 3, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by DerShung Yang, PhD, President, BrightOutcome
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2022